Medical marijuana is gaining in popularity among a wide range of patients as legalization expands, but those who are considering trying the new medication might be wary of its safety profile due to the relatively few clinical studies that exist and marijuana's schedule I status. Now, patients can find one more reason to rest assured as the director of the National Institute on Drug Abuse (NIDA) Nora Volkow has confirmed cannabidiol (CBD), one of the key non-psychoactive cannabinoids in marijuana, is both therapeutic and safe.
Volkow testified before the Senate in an attempt to knock down the barriers hindering scientific research surrounding CBD due to its Schedule I status. She said CBD is not only safe, but that it may also have the ability to buffer and counteract some of THC's psychocative effects. Volkow commented on CBD's great potential as a therapeutic component for a variety of applications, and said she will do anything in her power to remove the obstacles preventing medical marijuana research.
This information has been brought to you by Marijuana Health Wellness and approved by our Chief Medical Officer.